{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:16:44Z","timestamp":1788236204198,"version":"build-2803163510"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10142-026-02026-4","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:43:42Z","timestamp":1788234222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR\u2013cas systems in pharmacology: functional pharmacogenomics, drug screening, resistance, and therapeutic translation"],"prefix":"10.1007","volume":"26","author":[{"given":"Muhammad Saeed","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-6703","authenticated-orcid":false,"given":"Adnan","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"O Abudayyeh","year":"2017","unstructured":"Abudayyeh O, Gootenberg J, Essletzbichler P, Han S, Joung J, Belanto J, Verdine V, Cox D, Kellner M, Regev A, Lander E, Voytas D, Ting A, Zhang F (2017) RNA targeting with CRISPR-Cas13a. Nature 550:280\u2013284. https:\/\/doi.org\/10.1038\/nature24049","journal-title":"Nature"},{"key":"2026_CR2","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.2147\/idr.s494327","volume":"17","author":"M Ahmed","year":"2024","unstructured":"Ahmed M, Kayode HH, Okesanya O, Ukoaka B, Eshun G, Mourid MR, Adigun OA, Ogaya J, Mohamed ZO, Lucero-Prisno D (2024) CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions. Infect Drug Resist 17:5229\u20135245. https:\/\/doi.org\/10.2147\/idr.s494327","journal-title":"Infect Drug Resist"},{"key":"2026_CR3","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2147\/ijn.s453566","volume":"19","author":"K Allemailem","year":"2024","unstructured":"Allemailem K (2024) Recent Advances in Understanding the Molecular Mechanisms of Multidrug Resistance and Novel Approaches of CRISPR\/Cas9-Based Genome-Editing to Combat This Health Emergency. Int J Nanomed 19:1125\u20131143. https:\/\/doi.org\/10.2147\/ijn.s453566","journal-title":"Int J Nanomed"},{"key":"2026_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ng.3374","volume":"47","author":"F Aminkeng","year":"2015","unstructured":"Aminkeng F, Bhavsar A, Visscher H, Rassekh S, Li Y, Lee J, Brunham L, Caron H, Van Dalen E, Kremer L, Van Der Pal H, Amstutz U, Rieder M, Bernstein D, Carleton B, Hayden M, Ross C, Ross C, Macleod S, Smith A, Hildebrand C, Ghannadan R, Miao F, Higginson M, Massah N, Borrie A, Hughes S, Shaw K, Dhoot S, Bhavsar A, Kowalec K, Stortz J, Bendyshe-Walton T, Waltrip D, Bader R, Nijssen-Jordan C, Johnson D, Verbeek L, Kaczowka R, Stevenson P, Zhuwaki C, Grundy P, Stobart K, Wilson B, Desai S, Spavor M, Churcher L, Chow T-K, Hall K, Honcharik N, Israels S, Chan S, Garnham B, Staub M, Jong Gt, Malkin B, Portwine C, Cranston A, Koren G, Ito S, Nathan P, Greenberg M, Bournissen F, Inoue M, Sakaguchi S, Tanaka T, Fujii H, Ogawa M, Ingram R, Kamiya T, Karande S, Ghayoori S, Silva M, Willing S, Vaillancourt R, Johnston D, Mankoo H, Wong E, Wilson B, O\u2019Connor L, Hui C, Yuen C, Bussi\u00e8res J, Lebel D, Barret P, Clauson A, Courbon E, Cerruti L, Jabado N, Santo A, Nagy M, Murray M, Boliver D, Tiller M, Osborne C-A, Goodyear L, Bowes L, Kean N, Hand J (2015) A Coding Variant in RARG Confers Susceptibility to Anthracycline-Induced Cardiotoxicity in Childhood Cancer. Nat Genet 47:1079\u20131084. https:\/\/doi.org\/10.1038\/ng.3374","journal-title":"Nat Genet"},{"key":"2026_CR164","doi-asserted-by":"publisher","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa A, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A Liu DR (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576:149\u2013157. https:\/\/doi.org\/10.1038\/s41586-019-1711-4","DOI":"10.1038\/s41586-019-1711-4"},{"key":"2026_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1746-4811-9-39","volume":"9","author":"K Belhaj","year":"2013","unstructured":"Belhaj K, Chaparro-Garcia A, Kamoun S, Nekrasov V (2013) Plant genome editing made easy: targeted mutagenesis in model and crop plants using the CRISPR\/Cas system. Plant Methods 9:39\u201339. https:\/\/doi.org\/10.1186\/1746-4811-9-39","journal-title":"Plant Methods"},{"key":"2026_CR6","doi-asserted-by":"publisher","unstructured":"Bhat A, Nisar S, Mukherjee S, Saha N, Yarravarapu N, Lone S, Masoodi TA, Chauhan R, Maacha S, Bagga P, Dhawan P, Akil A, El-Rifai W, Uddin S, Reddy R, Singh M, Macha M, Haris M (2022) Integration of CRISPR\/Cas9 with artificial intelligence for improved cancer therapeutics. J Translational Med 20. https:\/\/doi.org\/10.1186\/s12967-022-03765-1","DOI":"10.1186\/s12967-022-03765-1"},{"key":"2026_CR7","doi-asserted-by":"publisher","unstructured":"Carullo N, Hinds J, Revanna J, Tuscher J, Bauman A, Day J (2021) A Cre-Dependent CRISPR\/dCas9 System for Gene Expression Regulation in Neurons. eNeuro 8. https:\/\/doi.org\/10.1523\/eneuro.0188-21.2021","DOI":"10.1523\/eneuro.0188-21.2021"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1093\/nar\/gkad255","volume":"51","author":"A Carusillo","year":"2023","unstructured":"Carusillo A, Haider S, Sch\u00e4fer R, Rhiel M, T\u00fcrk D, Chmielewski K, Klermund J, Mosti L, Andrieux G, Sch\u00e4fer R, Cornu T, Cathomen T, Mussolino C (2023) A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells. Nucleic Acids Res 51:4660\u20134673. https:\/\/doi.org\/10.1093\/nar\/gkad255","journal-title":"Nucleic Acids Res"},{"key":"2026_CR9","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/atvbaha.117.309881","volume":"37","author":"A Chadwick","year":"2017","unstructured":"Chadwick A, Wang X, Musunuru K (2017) In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. Arterioscler Thromb Vasc Biol 37:1741. https:\/\/doi.org\/10.1161\/atvbaha.117.309881","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10565-019-09486-4","volume":"35","author":"S-J Chen","year":"2019","unstructured":"Chen S-J (2019) Minimizing Off-target Effects in CRISPR-Cas9 Genome Editing. Cell Biol Toxicol 35:399\u2013401. https:\/\/doi.org\/10.1007\/s10565-019-09486-4","journal-title":"Cell Biol Toxicol"},{"key":"2026_CR10","doi-asserted-by":"publisher","unstructured":"Chen C, Wang Z-K, Qin Y (2023) CRISPR\/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy. Experimental Hematol Oncol 12. https:\/\/doi.org\/10.1186\/s40164-023-00457-4","DOI":"10.1186\/s40164-023-00457-4"},{"key":"2026_CR162","doi-asserted-by":"publisher","unstructured":"Chen S, Yu X, Guo D (2018) CRISPR-Cas targeting of host genes as an antiviral strategy. Viruses 10(1):40. https:\/\/doi.org\/10.3390\/v10010040","DOI":"10.3390\/v10010040"},{"key":"2026_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson L, Dilliard S, Siegwart D (2020) Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR\/Cas gene editing. Nat Nanotechnol 15:313\u2013320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6","journal-title":"Nat Nanotechnol"},{"key":"2026_CR13","doi-asserted-by":"publisher","unstructured":"Christidi E, Huang H, Shafaattalab S, Maillet A, Lin E, Huang K, Laksman Z, Davis M, Tibbits G, Brunham L (2020) Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes. Sci Rep 10. https:\/\/doi.org\/10.1038\/s41598-020-65979-x","DOI":"10.1038\/s41598-020-65979-x"},{"key":"2026_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2600931","author":"D Cohn","year":"2026","unstructured":"Cohn D, Gurugama P, Longhurst H, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Craig T, Farkas H, Jacobs J, Lumry W, Magerl M, Peter J, Riedl M, Maag D, Golden A, Shah M, Sutherland A, Miller C, Abdelhady A, Xu Y, Butler J, Lebwohl D, Leonard J, Banerji A (2026) Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2600931","journal-title":"N Engl J Med"},{"key":"2026_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/fpc.0000000000000402","volume":"30","author":"J Collins","year":"2020","unstructured":"Collins J, Wang D (2020) cis-acting regulatory elements regulating CYP3A4 transcription in human liver. Pharmacogenet Genomics 30:107\u2013116. https:\/\/doi.org\/10.1097\/fpc.0000000000000402","journal-title":"Pharmacogenet Genomics"},{"key":"2026_CR15","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/cts.13398","volume":"15","author":"J Collins","year":"2022","unstructured":"Collins J, Nworu A, Mohammad S, Li L, Li C, Li C, Schwendeman E, Cefalu M, Abdel-Rasoul M, Sun J, Smith S, Wang D (2022) Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5. Clin Transl Sci 15:2720\u20132731. https:\/\/doi.org\/10.1111\/cts.13398","journal-title":"Clin Transl Sci"},{"key":"2026_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339(6121):819\u2013823. https:\/\/doi.org\/10.1126\/science.1231143","journal-title":"Science"},{"key":"2026_CR18","first-page":"625","volume":"90","author":"AP Cribbs","year":"2017","unstructured":"Cribbs AP, Perera SMW (2017) Science and bioethics of CRISPR-Cas9 gene editing: an analysis towards separating facts and fiction. Yale J Biol Med 90:625","journal-title":"Yale J Biol Med"},{"key":"2026_CR19","doi-asserted-by":"publisher","unstructured":"Criscione S, Martin M, Oien D, Gorthi A, Miragaia R, Zhang J, Chen H, Karl D, Mendler K, Markovets A, Gagrica S, Delpuech O, Dry J, Grondine M, Hattersley M, Urosevic J, Floc\u2019h N, Drew L, Yao Y, Smith P (2022) The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. NPJ Precision Oncol 6. https:\/\/doi.org\/10.1038\/s41698-022-00337-w","DOI":"10.1038\/s41698-022-00337-w"},{"key":"2026_CR20","doi-asserted-by":"publisher","unstructured":"Dai W, Zhu L-Y, Yan ZY, Xu Y, Wang Q-L, Lu X-J (2016) CRISPR-Cas9 for in vivo gene therapy: promise and hurdles. Mol Ther Nucleic Acids 5. https:\/\/doi.org\/10.1038\/mtna.2016.58","DOI":"10.1038\/mtna.2016.58"},{"key":"2026_CR21","doi-asserted-by":"publisher","unstructured":"De Masi C, Spitalieri P, Murdocca M, Novelli G, Sangiuolo F (2020) Application of CRISPR\/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Hum Genomics 14. https:\/\/doi.org\/10.1186\/s40246-020-00276-2","DOI":"10.1186\/s40246-020-00276-2"},{"key":"2026_CR22","doi-asserted-by":"publisher","unstructured":"Dempster J, Pacini C, Pantel S, Behan F, Green T, Krill-Burger J, Beaver C, Younger S, Zhivich V, Najgebauer H, Allen F, Gon\u00e7alves E, Shepherd R, Doench J, Yusa K, Vazquez F, Parts L, Boehm J, Golub T, Hahn W, Root D, Garnett M, Iorio F, Tsherniak A (2019) Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nat Commun 10. https:\/\/doi.org\/10.1038\/s41467-019-13805-y","DOI":"10.1038\/s41467-019-13805-y"},{"key":"2026_CR23","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.3390\/cimb46050255","volume":"46","author":"E Deneault","year":"2024","unstructured":"Deneault E (2024) Recent Therapeutic Gene Editing Applications to Genetic Disorders. Curr Issues Mol Biol 46:4147\u20134185. https:\/\/doi.org\/10.3390\/cimb46050255","journal-title":"Curr Issues Mol Biol"},{"key":"2026_CR24","doi-asserted-by":"publisher","unstructured":"Dixit S, Kumar A, Srinivasan K, Durai P, Vincent R, Krishnan NR, Gomes C, Jamshidi E, Marchisio MA, Ramu N, Krishnan A (2024) Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions. Front Bioeng Biotechnol 11. https:\/\/doi.org\/10.3389\/fbioe.2023.1335901","DOI":"10.3389\/fbioe.2023.1335901"},{"key":"2026_CR25","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/nar\/gkaa897","volume":"48","author":"R Eki","year":"2020","unstructured":"Eki R, She J, Parlak M, Benamar M, Du K-P, Kumar P, Abbas T (2020) A robust CRISPR\u2013Cas9-based fluorescent reporter assay for the detection and quantification of DNA double-strand break repair. Nucleic Acids Res 48:e126\u2013e126","journal-title":"Nucleic Acids Res"},{"key":"2026_CR26","doi-asserted-by":"publisher","unstructured":"Emran T, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MFR, Ahmed H, Rahman N, Nainu F, Wahyudin E, Mitra S, Dhama K, Habiballah M, Haque S, Islam A, Hassan M (2022) Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.891652","DOI":"10.3389\/fonc.2022.891652"},{"key":"2026_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/15265161.2015.1104160","volume":"15","author":"N Evitt","year":"2015","unstructured":"Evitt N, Mascharak S, Altman R (2015) Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework. Am J Bioeth 15:25\u201329. https:\/\/doi.org\/10.1080\/15265161.2015.1104160","journal-title":"Am J Bioeth"},{"key":"2026_CR28","doi-asserted-by":"publisher","unstructured":"Far BF, Akbari M, Habibi MA, Katavand M, Nasseri S (2025) CRISPR Technology in disease management: an updated review of clinical translation and therapeutic potential. Cell Prolif 58. https:\/\/doi.org\/10.1111\/cpr.70099","DOI":"10.1111\/cpr.70099"},{"key":"2026_CR29","doi-asserted-by":"publisher","unstructured":"Fortin J, Tan J, Gascoigne K, Haverty P, Forrest W, Costa M, Martin S (2019) Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens. Genome Biol 20. https:\/\/doi.org\/10.1186\/s13059-019-1621-7","DOI":"10.1186\/s13059-019-1621-7"},{"key":"2026_CR152","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41588-021-00779-1","volume":"53","author":"C Frangieh","year":"2021","unstructured":"Frangieh C, Melms J, Thakore P, Geiger-Schuller K, Ho P, Luoma A, Cleary B, Jerby-Arnon L, Malu S, Cuoco M, Zhao M, Ager C, Rogava M, Hovey L, Rotem A, Bernatchez C, WucherpfennigK, Johnson B, Rozenblatt-Rosen O, Schadendorf D, Regev A, Izar B (2021) Multi-modal pooled Perturb-CITE-Seq screens in patient models define novelmechanisms of cancer immune evasion. Nat Genet 53:332\u2013341. https:\/\/doi.org\/10.1038\/s41588-021-00779-1","journal-title":"Nat Genet"},{"key":"2026_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2309676","author":"H Frangoul","year":"2024","unstructured":"Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem R, Telfer P, Shah A, Cavazzana M, Corbacioglu S, Rondelli D, Meisel R, Dedeken L, Lobitz S, De Montalembert M, Steinberg M, Walters M, Eckrich M, Imren S, Bower L, Simard C, Zhou W, Xuan F, Morrow P, Hobbs W, Grupp S (2024a) Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2309676","journal-title":"N Engl J Med"},{"key":"2026_CR31","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, Cavazzana M, Corbacioglu S, Rondelli D, Meisel R, Dedeken L, Lobitz S, de Montalembert M, Steinberg MH, Walters MC, Eckrich MJ, Imren S, Bower L, Simard C, Zhou W, Xuan F, Morrow PK, Hobbs WE, Grupp SA (2024b) Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med 390:1649\u20131662. https:\/\/doi.org\/10.1056\/NEJMoa2309676","journal-title":"N Engl J Med"},{"key":"2026_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41587-023-01759-y","volume":"42","author":"YE Gencay","year":"2024","unstructured":"Gencay YE, Jasinskyt\u0117 D, Robert C, Semsey S, Mart\u00ednez V, Petersen A\u00d8, Brunner K, de Santiago Torio A, Salazar A, Turcu IC (2024) Engineered phage with antibacterial CRISPR\u2013Cas selectively reduce E. coli burden in mice. Nat Biotechnol 42:265\u2013274","journal-title":"Nat Biotechnol"},{"key":"2026_CR33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"L Gilbert","year":"2014","unstructured":"Gilbert L, Horlbeck M, Adamson B, Villalta J, Chen Y, Whitehead E, Guimar\u00e3es C, Panning B, Ploegh H, Bassik M, Qi L, Kampmann M, Weissman J (2014a) Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159:647\u2013661. https:\/\/doi.org\/10.1016\/j.cell.2014.09.029","journal-title":"Cell"},{"key":"2026_CR34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC (2014b) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159:647\u2013661","journal-title":"Cell"},{"key":"2026_CR35","doi-asserted-by":"publisher","first-page":"16359","DOI":"10.1073\/pnas.1410806111","volume":"111","author":"B Gong","year":"2014","unstructured":"Gong B, Shin M, Sun J, Jung C-H, Bolt EL, Van Der Oost J, Kim J-S (2014a) Molecular insights into DNA interference by CRISPR-associated nuclease-helicase Cas3. Proc Natl Acad Sci 111:16359\u201316364","journal-title":"Proc Natl Acad Sci"},{"key":"2026_CR36","doi-asserted-by":"publisher","first-page":"16359","DOI":"10.1073\/pnas.1410806111","volume":"111","author":"B Gong","year":"2014","unstructured":"Gong B, Shin M, Sun J, Jung C, Bolt E, Van Der Oost J, Kim J-S (2014b) Molecular insights into DNA interference by CRISPR-associated nuclease-helicase Cas3. Proc Natl Acad Sci 111:16359\u201316364. https:\/\/doi.org\/10.1073\/pnas.1410806111","journal-title":"Proc Natl Acad Sci"},{"key":"2026_CR37","doi-asserted-by":"publisher","unstructured":"Gou X, Ran F, Yang J, Yan-rong, Wu X (2022) Construction and evaluation of a novel organic anion transporter 1\/3 CRISPR\/Cas9 double-knockout rat model. Pharmaceutics 14. https:\/\/doi.org\/10.3390\/pharmaceutics14112307","DOI":"10.3390\/pharmaceutics14112307"},{"key":"2026_CR38","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/14712598.2021.1869208","volume":"21","author":"C Graham","year":"2021","unstructured":"Graham C, Hart S (2021) CRISPR\/Cas9 gene editing therapies for cystic fibrosis. Expert Opin Biol Ther 21:767\u2013780. https:\/\/doi.org\/10.1080\/14712598.2021.1869208","journal-title":"Expert Opin Biol Ther"},{"key":"2026_CR39","doi-asserted-by":"publisher","unstructured":"Guo C, Xiaoteng, Gao F, Guo Y (2023) Off-target effects in CRISPR\/Cas9 gene editing. Front. Bioeng Biotechnol 11. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157","DOI":"10.3389\/fbioe.2023.1143157"},{"key":"2026_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-020-2099-x","volume":"580","author":"K Han","year":"2020","unstructured":"Han K, Pierce S, Li A, Spees K, Anderson G, Seoane J, Lo Y, Dubreuil M, Olivas M, Kamber R, Wainberg M, Kostyrko K, Kelly M, Yousefi M, Simpkins S, Yao D, Lee K, Kuo C, Jackson P, Sweet-Cordero A, Kundaje A, Gentles A, Curtis C, Winslow M, Bassik M (2020a) CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature 580:136\u2013141. https:\/\/doi.org\/10.1038\/s41586-020-2099-x","journal-title":"Nature"},{"key":"2026_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-020-2099-x","volume":"580","author":"K Han","year":"2020","unstructured":"Han K, Pierce SE, Li A, Spees K, Anderson GR, Seoane JA, Lo Y-H, Dubreuil M, Olivas M, Kamber RA (2020b) CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature 580:136\u2013141","journal-title":"Nature"},{"key":"2026_CR42","doi-asserted-by":"publisher","unstructured":"He P, Cao F, Qu Q, Geng H, Yang X, Xu T, Wang R, Jia X, Lu M, Zeng P, Luan G (2024) Host range expansion of Acinetobacter phage vB_Ab4_Hep4 driven by a spontaneous tail tubular mutation. Front Cell Infect Microbiol 14. https:\/\/doi.org\/10.3389\/fcimb.2024.1301089","DOI":"10.3389\/fcimb.2024.1301089"},{"key":"2026_CR43","doi-asserted-by":"publisher","unstructured":"Hirsch F, Iphofen R, Koporc Z (2019) Ethics assessment in research proposals adopting CRISPR technology. Biochemia Med 29. https:\/\/doi.org\/10.11613\/bm.2019.020202","DOI":"10.11613\/bm.2019.020202"},{"key":"2026_CR44","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.xgen.2022.100095","volume":"2","author":"C Hirt","year":"2022","unstructured":"Hirt C, Booij T, Grob L, Simmler P, Toussaint N, Keller D, Taube D, Ludwig V, Goryachkin A, Pauli C, Lenggenhager D, Stekhoven D, Stirnimann C, Endhardt K, Ringnalda F, Villiger L, Siebenh\u00fcner A, Karkampouna S, De Menna M, Beshay J, Klett H, Julio MK-D, Sch\u00fcler J, Schwank G (2022) Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Cell genomics 2:100095\u2013100095. https:\/\/doi.org\/10.1016\/j.xgen.2022.100095","journal-title":"Cell genomics"},{"key":"2026_CR45","doi-asserted-by":"publisher","unstructured":"Hou J, He Z, Liu T, Chen D, Wang B, Wen Q, Zheng X (2022) Evolution of molecular targeted cancer therapy: mechanisms of drug resistance and novel opportunities Identified by CRISPR-Cas9 screening. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.755053","DOI":"10.3389\/fonc.2022.755053"},{"key":"2026_CR46","doi-asserted-by":"publisher","unstructured":"Hu Y-X, Zu C, Zhang M, Wei G, Li W, Fu S, Hong R, Zhou L, Wu W-J, Cui J, Wang D, Du B, Liu M, Zhang J, Huang H (2023) Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: a first-in-human phase I study. eClinicalMedicine 60. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102010","DOI":"10.1016\/j.eclinm.2023.102010"},{"key":"2026_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1021\/acssynbio.2c00465","volume":"12","author":"Y Huan","year":"2022","unstructured":"Huan Y, Torraca V, Brown R, Fa-Arun J, Miles S, Oyarz\u00fan D, Mostowy S, Wang B (2022) P1 Bacteriophage-Enabled Delivery of CRISPR-Cas9 Antimicrobial Activity Against Shigella flexneri. ACS Synth Biol 12:709\u2013721. https:\/\/doi.org\/10.1021\/acssynbio.2c00465","journal-title":"ACS Synth Biol"},{"key":"2026_CR48","doi-asserted-by":"publisher","unstructured":"Huang L, Liao Z, Liu Z, Chen Y, Huang T, Xiao H (2022) Application and prospect of CRISPR\/Cas9 technology in reversing drug resistance of non-small cell lung cancer. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/fphar.2022.900825","DOI":"10.3389\/fphar.2022.900825"},{"key":"2026_CR50","doi-asserted-by":"publisher","unstructured":"Jamalinia M, Weiskirchen R (2025) Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. Annals Translational Med 13. https:\/\/doi.org\/10.21037\/atm-25-34","DOI":"10.21037\/atm-25-34"},{"key":"2026_CR51","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science 337:816\u2013821","journal-title":"Science"},{"key":"2026_CR52","doi-asserted-by":"publisher","unstructured":"Joung J, Kirchgatterer P, Singh A, Cho J, Nety S, Larson R, Macrae R, Deasy R, Tseng Y-Y, Maus M, Zhang F (2022) CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun 13. https:\/\/doi.org\/10.1038\/s41467-022-29205-8","DOI":"10.1038\/s41467-022-29205-8"},{"key":"2026_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pbiomolbio.2018.07.008","volume":"141","author":"R Kabra","year":"2018","unstructured":"Kabra R, Chauhan N, Kumar A, Ingale P, Singh S (2018) Efflux pumps and antimicrobial resistance: Paradoxical components in systems genomics. Prog Biophys Mol Biol 141:15\u201324. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2018.07.008","journal-title":"Prog Biophys Mol Biol"},{"key":"2026_CR54","doi-asserted-by":"publisher","unstructured":"Kannan S, Najjar D (2020) Therapeutic gene editing is here, can regulations keep up? 1:64\u201375. https:\/\/doi.org\/10.38105\/spr.czm9c2w8ig","DOI":"10.38105\/spr.czm9c2w8ig"},{"key":"2026_CR55","doi-asserted-by":"publisher","unstructured":"Kawaguchi T, Watanabe S, Liu Y, Aiba Y, Tan X-E, Veeranarayanan S, Miyanaga K, Sasahara T, Shimamori Y, Alessa O, Hidaka Y, Thu M, Kaewprasert O, Rani V, Hossain MR, Palaninathan V, Esakkiraj P, Fatwa T, Hakim N, Maruthan K, Fernandes P, Arbaah M, Batbold A, Hossain S, Sugano T, Uematsu H, Wannigama D, Kiga K, Cui L (2025) Gene-specific reversal of carbapenem-resistant Pseudomonas aeruginosa via phage-delivered CRISPR-Cas13a. npj Antimicrobials and Resistance 3. https:\/\/doi.org\/10.1038\/s44259-025-00167-3","DOI":"10.1038\/s44259-025-00167-3"},{"key":"2026_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/jpm2020035","volume":"2","author":"F Kelleher","year":"2012","unstructured":"Kelleher F, Solomon B, McArthur G (2012) Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer. J Personalized Med 2:35\u201349. https:\/\/doi.org\/10.3390\/jpm2020035","journal-title":"J Personalized Med"},{"key":"2026_CR153","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.1002\/jcp.27476","volume":"234","author":"S Khadempar","year":"2019","unstructured":"Khadempar S, Familghadakchi S, Motlagh RA, Farahani N, Dashtiahangar M, Rezaei H, Gheibi Hayat SM (2019) CRISPR\u2013Cas9 in genome editing: Its function and medical applications. J ofcellular Physiol 234:5751\u20135761","journal-title":"J ofcellular Physiol"},{"key":"2026_CR57","doi-asserted-by":"publisher","unstructured":"Khoshandam M, Soltaninejad H, Hamidieh A, Hosseinkhani S (2023) CRISPR, CAR-T, and NK: Current applications and future perspectives. Genes Dis 11. https:\/\/doi.org\/10.1016\/j.gendis.2023.101121","DOI":"10.1016\/j.gendis.2023.101121"},{"key":"2026_CR58","doi-asserted-by":"publisher","unstructured":"Kiernan K, Kwon J, Merrill B, Simonovi\u0107 M (2025) Structural basis of Cas9 DNA interrogation with a 5\u2032 truncated sgRNA. Nucleic Acids Res 53. https:\/\/doi.org\/10.1093\/nar\/gkae1164","DOI":"10.1093\/nar\/gkae1164"},{"key":"2026_CR59","doi-asserted-by":"publisher","unstructured":"Kiga K, Tan X-E, Ibarra-Ch\u00e1vez R, Watanabe S, Aiba Y, Sato\u2019o Y, Li F-Y, Sasahara T, Cui B, Kawauchi M, Boonsiri T, Thitiananpakorn K, Taki Y, Azam A, Suzuki M, Penad\u00e9s J, Cui L (2020) Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nat Commun 11. https:\/\/doi.org\/10.1038\/s41467-020-16731-6","DOI":"10.1038\/s41467-020-16731-6"},{"key":"2026_CR61","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.4014\/jmb.2008.08058","volume":"30","author":"B Kim","year":"2020","unstructured":"Kim B, Kim H, Lee S (2020) Effective Blocking of Microbial Transcriptional Initiation by dCas9-NG-Mediated CRISPR Interference. J Microbiol Biotechnol 30:1919\u20131926. https:\/\/doi.org\/10.4014\/jmb.2008.08058","journal-title":"J Microbiol Biotechnol"},{"key":"2026_CR62","doi-asserted-by":"publisher","unstructured":"Kim M, Hwang Y, Lim S, Jang H-K, Kim H-O (2024) Advances in nanoparticles as non-viral vectors for efficient delivery of CRISPR\/Cas9. Pharmaceutics 16. https:\/\/doi.org\/10.3390\/pharmaceutics16091197","DOI":"10.3390\/pharmaceutics16091197"},{"key":"2026_CR63","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"B Kleinstiver","year":"2015","unstructured":"Kleinstiver B, Pattanayak V, Prew M, Tsai S, Nguyen N, Zheng Z, Joung J (2015) High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets. Nature 529:490\u2013495. https:\/\/doi.org\/10.1038\/nature16526","journal-title":"Nature"},{"key":"2026_CR64","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/nar\/gkad1130","volume":"52","author":"SC Ko","year":"2024","unstructured":"Ko SC, Woo HM (2024) CRISPR\u2013dCas13a system for programmable small RNAs and polycistronic mRNA repression in bacteria. Nucleic Acids Res 52:492\u2013506","journal-title":"Nucleic Acids Res"},{"key":"2026_CR65","doi-asserted-by":"publisher","first-page":"262","DOI":"10.34172\/apb.2022.027","volume":"12","author":"VA Kordkheyli","year":"2022","unstructured":"Kordkheyli VA, Rashidi M, Shokri Y, Fallahpour S, Variji A, Ghara EN, Hosseini S (2022) CRISPER\/CAS System, a Novel Tool of Targeted Therapy of Drug-Resistant Lung Cancer. Adv Pharm Bull 12:262\u2013273. https:\/\/doi.org\/10.34172\/apb.2022.027","journal-title":"Adv Pharm Bull"},{"key":"2026_CR66","doi-asserted-by":"publisher","unstructured":"Kubikova N, Keefe D, Wells D, Oktay K, Feinberg E (2023) Should we use CRISPR gene editing in human embryos? Fertility and sterility. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.08.009","DOI":"10.1016\/j.fertnstert.2023.08.009"},{"key":"2026_CR67","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/s0140-6736(23)00560-3","volume":"401 10380","author":"T Lancet","year":"2023","unstructured":"Lancet T (2023) Human genome editing: ensuring responsible research. Lancet 401 10380:877. https:\/\/doi.org\/10.1016\/s0140-6736(23)00560-3","journal-title":"Lancet"},{"key":"2026_CR68","doi-asserted-by":"publisher","unstructured":"Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas C, Frock R, Kenrick J, Lee C, Talbott N, Skowronski J, Cromer M, Charlesworth C, Bak R, Mantri S, Bao G, Digiusto D, Tisdale J, Wright J, Bhatia N, Roncarolo M, Dever D, Porteus M (2021) Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med 13. https:\/\/doi.org\/10.1126\/scitranslmed.abf2444","DOI":"10.1126\/scitranslmed.abf2444"},{"key":"2026_CR69","doi-asserted-by":"publisher","unstructured":"Laurent M, Geoffroy M, Pavani G, Guiraud S (2024) CRISPR-Based gene therapies: from preclinical to clinical treatments. Cells 13. https:\/\/doi.org\/10.3390\/cells13100800","DOI":"10.3390\/cells13100800"},{"key":"2026_CR158","doi-asserted-by":"publisher","unstructured":"Le Sage C, Lawo S, PanickerP, Scales TME, Rahman SA, Little AS, McCarthy NJ, Moore JD, Cross BCS (2017) Dual direction CRISPR transcriptional regulation screening uncoversgene networks driving drug resistance. Scientific Reports 7:17693. https:\/\/doi.org\/10.1038\/s41598-017-18172-6","DOI":"10.1038\/s41598-017-18172-6"},{"key":"2026_CR161","doi-asserted-by":"publisher","unstructured":"Lee C (2019) CRISPR\/Cas9-based antiviral strategy: current status and the potential challenge. Molecules 24(7):1349. https:\/\/doi.org\/10.3390\/molecules24071349","DOI":"10.3390\/molecules24071349"},{"key":"2026_CR70","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/mco2.106","volume":"2","author":"Z Lei","year":"2021","unstructured":"Lei Z, Teng Q, Wu Z, Ping F, Song P, Wurpel J, Chen Z-S (2021) Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR\/Cas9 system in SW620\/Ad300 colorectal cancer cells. MedComm 2:765\u2013777. https:\/\/doi.org\/10.1002\/mco2.106","journal-title":"MedComm"},{"key":"2026_CR71","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","volume":"28","author":"A Li","year":"2020","unstructured":"Li A, Tanner M, Lee C, Hurley A, De Giorgi M, Jarrett K, Davis T, Doerfler A, Bao G, Beeton C, Lagor W (2020) AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. Mol Ther 28:1432\u20131441. https:\/\/doi.org\/10.1016\/j.ymthe.2020.04.017","journal-title":"Mol Ther"},{"key":"2026_CR72","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.2147\/idr.s357470","volume":"15","author":"P Li","year":"2022","unstructured":"Li P, Wan P, Zhao R, Chen J, Li X, Li J, Xiong W, Zeng Z (2022) Targeted Elimination of blaNDM-5 Gene in Escherichia coli by Conjugative CRISPR-Cas9 System. Infect Drug Resist 15:1707\u20131716. https:\/\/doi.org\/10.2147\/idr.s357470","journal-title":"Infect Drug Resist"},{"key":"2026_CR73","doi-asserted-by":"publisher","unstructured":"Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, He X, Liu M, Li P-F, Yu T (2023) CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther 8. https:\/\/doi.org\/10.1038\/s41392-023-01309-7","DOI":"10.1038\/s41392-023-01309-7"},{"key":"2026_CR75","doi-asserted-by":"publisher","unstructured":"Lin Y, Wagner E, L\u00e4chelt U (2022) Non-viral delivery of the CRISPR\/Cas system: DNA versus RNA versus RNP. Biomaterials science. https:\/\/doi.org\/10.1039\/d1bm01658j","DOI":"10.1039\/d1bm01658j"},{"key":"2026_CR78","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2017.06.050","volume":"170 4","author":"L Liu","year":"2017","unstructured":"Liu L, Li X, Jun, Li Z, You L, Wang J, Wang M, Zhang X, Wang Y (2017) The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a. Cell 170 4:714\u2013726. https:\/\/doi.org\/10.1016\/j.cell.2017.06.050","journal-title":"Cell"},{"key":"2026_CR76","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.drudis.2019.02.011","volume":"24 4","author":"B Liu","year":"2019","unstructured":"Liu B, Saber A, Haisma H (2019) CRISPR\/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discovery Today 24 4:955\u2013970. https:\/\/doi.org\/10.1016\/j.drudis.2019.02.011","journal-title":"Drug Discovery Today"},{"key":"2026_CR77","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/procel\/pwad013","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, Chen Y, Nong B, Luo X, Cui K, Tan W, Yang Y, Wenbin, Liang P, Songyang Z (2023) CRISPR-assisted transcription activation by phase-separation proteins. Protein Cell 14:874\u2013887. https:\/\/doi.org\/10.1093\/procel\/pwad013","journal-title":"Protein Cell"},{"key":"2026_CR79","doi-asserted-by":"publisher","unstructured":"Liu S, Zou C, Pak J, Morse A, Pang D, Casey-Clyde T, Borah A, Wu D, Seo K, O\u2019Loughlin T, Lim D, Ozawa T, Berger M, Kamber R, Weiss W, Raleigh D, Gilbert L (2024) In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma. Genome Biol 25. https:\/\/doi.org\/10.1186\/s13059-024-03404-6","DOI":"10.1186\/s13059-024-03404-6"},{"key":"2026_CR80","doi-asserted-by":"publisher","unstructured":"Lo Y-H, Horn H, Huang M-F, Yu W, Young C-M, Liu Q, Tomaske M, Towers M, Dominguez A, Bassik M, Lee D-F, Qi L, Weissman J, Chen J, Kuo C (2025) Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions. Nat Commun 16. https:\/\/doi.org\/10.1038\/s41467-025-62818-3","DOI":"10.1038\/s41467-025-62818-3"},{"key":"2026_CR81","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2309673","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li A, De La Fuente J, Shah A, Carpenter B, Kwiatkowski J, Mapara M, Liem R, Cappellini M, Algeri M, Kattamis A, Sheth S, Grupp S, Handgretinger R, Kohli P, Shi D, Ross L, Bobruff Y, Simard C, Zhang L, Morrow P, Hobbs W, Frangoul H (2024a) Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2309673","journal-title":"N Engl J Med"},{"key":"2026_CR82","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, de la Fuente J, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara M, Liem RI, Cappellini MD, Algeri M, Kattamis A, Sheth S, Grupp S, Handgretinger R, Kohli P, Shi D, Ross L, Bobruff Y, Simard C, Zhang L, Morrow PK, Hobbs WE, Frangoul H (2024b) Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia. N Engl J Med 390:1663\u20131676. https:\/\/doi.org\/10.1056\/NEJMoa2309673","journal-title":"N Engl J Med"},{"key":"2026_CR83","doi-asserted-by":"publisher","unstructured":"Lorenzo D, Esquerda M, Palau F, Cambra F, Bio\u00e9tica GIE (2022) Ethics and genomic editing using the Crispr-Cas9 technique: challenges and conflicts. NanoEthics. https:\/\/doi.org\/10.1007\/s11569-022-00425-y","DOI":"10.1007\/s11569-022-00425-y"},{"key":"2026_CR156","doi-asserted-by":"publisher","unstructured":"Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823\u2013826. https:\/\/doi.org\/10.1126\/science.1232033","DOI":"10.1126\/science.1232033"},{"key":"2026_CR84","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Escobar A, Luna-Callejas B, Ram\u00f3n-Gallegos E (2021) CRISPR-dCas9-based artificial transcription factors to improve efficacy of cancer treatment with drug repurposing: proposal for future research. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.604948","DOI":"10.3389\/fonc.2020.604948"},{"key":"2026_CR85","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s13311-022-01197-9","volume":"19","author":"CH Mbakam","year":"2022","unstructured":"Mbakam CH, Lamothe G, Tremblay G, Tremblay J (2022) CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy. Neurotherapeutics 19:931\u2013941. https:\/\/doi.org\/10.1007\/s13311-022-01197-9","journal-title":"Neurotherapeutics"},{"key":"2026_CR163","doi-asserted-by":"publisher","unstructured":"McCoullough L, Fareh M, Hu W, Sozzi V, Makhlouf C, Droungas Y, Lee CL, Takawy M, Fabb SA, Payne T, Pouton C,Netter HJ, Lewin SR, Purcell D, Holmes J, Trapani JA, Littlejohn M, Revill PA (2024) CRISPR-Cas13b-mediated suppression of hepatitis B virusreplication and protein expression. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2024.05.025","DOI":"10.1016\/j.jhep.2024.05.025"},{"key":"2026_CR86","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt.1755","volume":"29","author":"JC Miller","year":"2011","unstructured":"Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29:143\u2013148. https:\/\/doi.org\/10.1038\/nbt.1755","journal-title":"Nat Biotechnol"},{"key":"2026_CR154","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41592-019-0392-0","volume":"16","author":"E Mimitou","year":"2019","unstructured":"Mimitou E, Cheng A, Montalbano A, Hao S, Stoeckius M, Legut M, Roush T, Herrera A, Papalexi E, Ouyang Z, SatijaR, Sanjana N, Koralov S, Smibert P (2019) Expanding the CITE-seq tool-kit: Detection of proteins, transcriptomes, clonotypes and CRISPR perturbationswith multiplexing, in a single assay. Nat Methods 16:409\u2013412. https:\/\/doi.org\/10.1038\/s41592-019-0392-0","journal-title":"Nat Methods"},{"key":"2026_CR87","doi-asserted-by":"publisher","first-page":"2201605","DOI":"10.1002\/smtd.202201605","volume":"7","author":"J Mircetic","year":"2023","unstructured":"Mircetic J, Camg\u00f6z A, Abohawya M, Ding L, Dietzel J, Tobar SG, Paszkowski-Rogacz M, Seidlitz T, Schm\u00e4che T, Mehnert MC (2023) CRISPR\/Cas9 screen in gastric cancer patient\u2010derived organoids reveals KDM1A\u2010NDRG1 Axis as a targetable vulnerability. Small methods 7:2201605","journal-title":"Small methods"},{"key":"2026_CR88","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/0008-5472.can-23-2729","volume":"83","author":"S Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay S, Huang H, Lin Z, Ranieri M, Li S, Sahu S, Liu Y, Ban Y, Guidry K, Hu H, Lopez A, Sherman F, Tan Y, Lee YT, Armstrong A, Dolgalev I, Sahu P, Zhang T, Lu W, Gray N, Christensen J, Tang T, Velcheti V, Khodadadi-Jamayran A, Wong KKS, Neel B (2023) Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy. Cancer Res 83:4095\u20134111. https:\/\/doi.org\/10.1158\/0008-5472.can-23-2729","journal-title":"Cancer Res"},{"key":"2026_CR89","doi-asserted-by":"publisher","unstructured":"Mulero-S\u00e1nchez A, Bosma A, Visuvasam B, Pouliopoulou N, Van De Ven M, Proost N, Boeije M, Lieftink C, Beijersbergen R, Bernards R, Mainardi S (2026) CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer. J Experimental Clin Cancer Research: CR 45. https:\/\/doi.org\/10.1186\/s13046-025-03616-z","DOI":"10.1186\/s13046-025-03616-z"},{"key":"2026_CR90","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/nejmoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, Grandinette S, Wang X, Hudson T, Briseno K, Berry A-M, Hacker J, Hsu A, Silverstein R, Hille L, Ogul A, Robinson-Garvin N, Small J, McCague S, Burke S, Wright C, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas C, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa C, Semple S, Tam Y, Lutz C, George L, Kleinstiver B, Liu D, Ng K, Kassim S, Giannikopoulos P, Alameh M, Urnov F, Ahrens-Nicklas R (2025a) Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med 392:2235\u20132243. https:\/\/doi.org\/10.1056\/nejmoa2504747","journal-title":"N Engl J Med"},{"key":"2026_CR91","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC (2025b) Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med 392:2235\u20132243. https:\/\/doi.org\/10.1056\/NEJMoa2504747","journal-title":"N Engl J Med"},{"key":"2026_CR92","doi-asserted-by":"publisher","unstructured":"Naknaen A, Samernate T, Wannasrichan W, Surachat K, Nonejuie P, Chaikeeratisak V (2023) Combination of genetically diverse Pseudomonas phages enhances the cocktail efficiency against bacteria. Sci Rep 13. https:\/\/doi.org\/10.1038\/s41598-023-36034-2","DOI":"10.1038\/s41598-023-36034-2"},{"key":"2026_CR93","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41929-022-00848-6","volume":"5","author":"\u0141 Nierzwicki","year":"2022","unstructured":"Nierzwicki \u0141, East KW, Binz JM, Hsu RV, Ahsan M, Arantes PR, Skeens E, Pacesa M, Jinek M, Lisi GP (2022) Principles of target DNA cleavage and the role of Mg2\u2009+\u2009in the catalysis of CRISPR\u2013Cas9. Nat Catal 5:912\u2013922","journal-title":"Nat Catal"},{"key":"2026_CR94","doi-asserted-by":"publisher","unstructured":"Nogel M (2025) Introducing CASGEVY in Europe: Ethical and Regulatory Perspectives on the First CRISPR Gene Therapy. Eur J Public Health 35. https:\/\/doi.org\/10.1093\/eurpub\/ckaf161.1353","DOI":"10.1093\/eurpub\/ckaf161.1353"},{"key":"2026_CR95","doi-asserted-by":"publisher","unstructured":"Palasantzas V, Tamargo-Rubio I, Le K, Slager J, Wijmenga C, Jonkers I, Kumar V, Fu J, Withoff S (2023) iPSC-derived organ-on-a-chip models for personalized human genetics and pharmacogenomics studies. Trends in genetics: TIG. https:\/\/doi.org\/10.1016\/j.tig.2023.01.002","DOI":"10.1016\/j.tig.2023.01.002"},{"key":"2026_CR96","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/laws5030036","volume":"5","author":"A Paor","year":"2016","unstructured":"Paor A, Blanck P (2016) Precision Medicine and Advancing Genetic Technologies\u2014Disability and Human Rights Perspectives. Laws 5:36. https:\/\/doi.org\/10.3390\/laws5030036","journal-title":"Laws"},{"key":"2026_CR98","doi-asserted-by":"publisher","unstructured":"Park JY, Moon B, Park J, Thornton J, Park Y, Seo K (2017) Genetic engineering of a temperate phage-based delivery system for CRISPR\/Cas9 antimicrobials against Staphylococcus aureus. Sci Rep 7. https:\/\/doi.org\/10.1038\/srep44929","DOI":"10.1038\/srep44929"},{"key":"2026_CR99","doi-asserted-by":"publisher","unstructured":"Park S, Cao M, Pan Y, Davis T, Saxena L, Deshmukh H, Fu Y, Treangen T, Sheehan V, Bao G (2022) Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing. Sci Adv 8. https:\/\/doi.org\/10.1126\/sciadv.abo7676","DOI":"10.1126\/sciadv.abo7676"},{"key":"2026_CR97","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41417-025-00959-9","volume":"32","author":"H Park","year":"2025","unstructured":"Park H, Yu S, Koo T (2025) Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine. Cancer Gene Ther 32:1293\u20131302. https:\/\/doi.org\/10.1038\/s41417-025-00959-9","journal-title":"Cancer Gene Ther"},{"key":"2026_CR100","doi-asserted-by":"publisher","first-page":"9527","DOI":"10.3390\/ijms24119527","volume":"24","author":"K Paschoudi","year":"2023","unstructured":"Paschoudi K, Yannaki E, Psatha N (2023) Precision editing as a therapeutic approach for \u03b2-hemoglobinopathies. Int J Mol Sci 24:9527","journal-title":"Int J Mol Sci"},{"key":"2026_CR101","doi-asserted-by":"publisher","unstructured":"Patel H, Patel N, Mathukiya S, Parekh B, Purohit KA, Patel S, Patel J (2025) Genomic medicine: applications in disease prevention and treatment. J Pharm Bioallied Sci 17. https:\/\/doi.org\/10.4103\/jpbs.jpbs_541_25","DOI":"10.4103\/jpbs.jpbs_541_25"},{"key":"2026_CR102","doi-asserted-by":"publisher","unstructured":"Pierce S, Granja J, Greenleaf W (2022) High-throughput single-cell chromatin accessibility CRISPR screens enable unbiased identification of regulatory networks in cancer. Nat Commun 12. https:\/\/doi.org\/10.1038\/s41467-021-23213-w","DOI":"10.1038\/s41467-021-23213-w"},{"key":"2026_CR103","doi-asserted-by":"publisher","unstructured":"Piergentili R, Del Rio A, Signore F, Ronchi U, Marinelli E, Zaami S (2021) CRISPR-Cas and its wide-ranging applications: from human genome editing to environmental implications, technical limitations, hazards and bioethical issues. Cells 10. https:\/\/doi.org\/10.3390\/cells10050969","DOI":"10.3390\/cells10050969"},{"key":"2026_CR104","doi-asserted-by":"publisher","unstructured":"Piotrowska Z, Sequist L (2017) Tackling the next generation of resistance in EGFR-mutant lung cancer. journal of thoracic oncology: official publication of the international association for the study of lung cancer. 12 3:419\u2013421. https:\/\/doi.org\/10.1016\/j.jtho.2017.01.018","DOI":"10.1016\/j.jtho.2017.01.018"},{"key":"2026_CR105","doi-asserted-by":"publisher","unstructured":"Pursey E, S\u00fcnderhauf D, Gaze W, Westra E, Van Houte S (2018) CRISPR-Cas antimicrobials: challenges and future prospects. PLoS Pathog 14. https:\/\/doi.org\/10.1371\/journal.ppat.1006990","DOI":"10.1371\/journal.ppat.1006990"},{"key":"2026_CR106","doi-asserted-by":"publisher","unstructured":"Qu J-R, Qiu B, Zhang Y, Hu Y, Wang Z, Guan Z, Qin Y, Sui T, Wu F, Li B, Han W, Peng X (2023) The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling. Signal Transduct Target Therapy 8. https:\/\/doi.org\/10.1038\/s41392-023-01666-3","DOI":"10.1038\/s41392-023-01666-3"},{"key":"2026_CR107","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1182\/bloodadvances.2019001346","volume":"4 13","author":"P Ramkumar","year":"2020","unstructured":"Ramkumar P, Abarientos A, Tian R, Seyler M, Leong J, Chen M, Choudhry P, Hechler T, Shah N, Wong S, Martin T, Wolf J, Roybal K, Pahl A, Taunton J, Wiita A, Kampmann M (2020) CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv 4 13:2899\u20132911. https:\/\/doi.org\/10.1182\/bloodadvances.2019001346","journal-title":"Blood Adv"},{"key":"2026_CR108","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"F Ran","year":"2015","unstructured":"Ran F, Cong L, Yan W, Scott D, Gootenberg J, Kriz A, Zetsche B, Shalem O, Wu X, Makarova K, Koonin E, Sharp P, Zhang F, Koch D (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186\u2013191. https:\/\/doi.org\/10.1038\/nature14299","journal-title":"Nature"},{"key":"2026_CR109","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11019-022-10115-x","volume":"26","author":"R Ranisch","year":"2022","unstructured":"Ranisch R, Trettenbach K, Arnason G (2022) Initial heritable genome editing: mapping a responsible pathway from basic research to the clinic. Med Healthc Philos 26:21\u201335. https:\/\/doi.org\/10.1007\/s11019-022-10115-x","journal-title":"Med Healthc Philos"},{"key":"2026_CR110","doi-asserted-by":"publisher","unstructured":"Rauf M, Rao A, Sivasoorian SS, Iyer A (2025) Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review. Cells 14. https:\/\/doi.org\/10.3390\/cells14151136","DOI":"10.3390\/cells14151136"},{"key":"2026_CR111","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.stem.2020.02.007","volume":"26 3","author":"T Ringel","year":"2020","unstructured":"Ringel T, Frey N, Ringnalda F, Janjuha S, Cherkaoui S, Butz S, Srivatsa S, Pirkl M, Russo G, Villiger L, Rogler G, Clevers H, Beerenwinkel N, Zamboni N, Baubec T, Schwank G (2020) Genome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF-\u03b2 Resistance. Cell Stem Cell 26 3:431\u2013440. https:\/\/doi.org\/10.1016\/j.stem.2020.02.007","journal-title":"Cell Stem Cell"},{"key":"2026_CR112","doi-asserted-by":"publisher","unstructured":"Sapp V, Aguirre A, Mainkar G, Ding J, Adler E, Liao R, Sharma S, Jain M (2021) Genome-wide CRISPR\/Cas9 screening in human iPS derived cardiomyocytes uncovers novel mediators of doxorubicin cardiotoxicity. Sci Rep 11. https:\/\/doi.org\/10.1038\/s41598-021-92988-1","DOI":"10.1038\/s41598-021-92988-1"},{"key":"2026_CR113","doi-asserted-by":"publisher","unstructured":"Schilling C, Koffas M, Sieber V, Schmid J (2020) Novel prokaryotic CRISPR-Cas12a-based tool for programmable transcriptional activation and repression. ACS synthetic biology. https:\/\/doi.org\/10.1021\/acssynbio.0c00424","DOI":"10.1021\/acssynbio.0c00424"},{"key":"2026_CR114","doi-asserted-by":"publisher","unstructured":"Selvakumar S, Preethi K, Ross K, Tusubira D, Khan M, Mani P, Rao T, Sekar D (2022) CRISPR\/Cas9 and next generation sequencing in the personalized treatment of Cancer. Mol Cancer 21. https:\/\/doi.org\/10.1186\/s12943-022-01565-1","DOI":"10.1186\/s12943-022-01565-1"},{"key":"2026_CR115","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/nejmoa2215643","volume":"389 9","author":"A Sharma","year":"2023","unstructured":"Sharma A, Boelens J, Cancio M, Hankins J, Bhad P, Azizy M, Lewandowski A, Zhao X, Chitnis S, Peddinti R, Zheng Y, Kapoor N, Ciceri F, Maclachlan T, Yang Y, Liu Y, Yuan J, Naumann U, Yu V, Stevenson S, De Vita S, LaBelle J (2023) CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. N Engl J Med 389 9:820\u2013832. https:\/\/doi.org\/10.1056\/nejmoa2215643","journal-title":"N Engl J Med"},{"key":"2026_CR116","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11673-019-09953-x","volume":"17","author":"D Shaw","year":"2020","unstructured":"Shaw D (2020) The Consent Form in the Chinese CRISPR Study: In Search of Ethical Gene Editing. J Bioethical Inq 17:5\u201310. https:\/\/doi.org\/10.1007\/s11673-019-09953-x","journal-title":"J Bioethical Inq"},{"key":"2026_CR117","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nbt.3235","volume":"33","author":"J Shi","year":"2015","unstructured":"Shi J, Wang E, Milazzo J, Wang Z, Kinney J, Vakoc C (2015) Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 33:661\u2013667. https:\/\/doi.org\/10.1038\/nbt.3235","journal-title":"Nat Biotechnol"},{"key":"2026_CR118","doi-asserted-by":"publisher","unstructured":"Shimamori Y, Tan X-E, Li F-Y, Nishikawa Y, Watanabe S, Sasahara T, Miyanaga K, Aiba Y, Veeranarayanan S, Thitiananpakorn K, Nguyen HM, Batbold A, Nayanjin T, Yeo A, Lian S, Hossain S, Kawaguchi T, Alessa O, Kumwenda G, Sarangi J, Revilleza J, Baranwal P, Arbaah M, Yi L, Thi H, Duy\u00ean M, Sugano T, Sultana S, Faruk M, Hidaka Y, Thu M, Shimojyo T, Kiga K, Cui L (2024) Efficient synthesis of CRISPR-Cas13a-antimicrobial capsids against MRSA facilitated by silent mutation incorporation. Sci Rep 14. https:\/\/doi.org\/10.1038\/s41598-024-67193-5","DOI":"10.1038\/s41598-024-67193-5"},{"key":"2026_CR119","doi-asserted-by":"publisher","first-page":"103","DOI":"10.21775\/cimb.026.103","volume":"26","author":"ZK Shinwari","year":"2018","unstructured":"Shinwari ZK, Tanveer F, Khalil AT (2018) Ethical issues regarding CRISPR mediated genome editing. Curr Issues Mol Biol 26:103\u2013110","journal-title":"Curr Issues Mol Biol"},{"key":"2026_CR120","doi-asserted-by":"publisher","DOI":"10.36948\/ijfmr.2025.v07i03.47872","author":"R Shukal","year":"2025","unstructured":"Shukal R (2025) Gene Editing and Reproductive Medicine: The Ethics of CRISPR in Obstetrics and Gynaecology. Int J Multidisciplinary Res. https:\/\/doi.org\/10.36948\/ijfmr.2025.v07i03.47872","journal-title":"Int J Multidisciplinary Res"},{"key":"2026_CR121","doi-asserted-by":"publisher","first-page":"33568","DOI":"10.1039\/d4ra06117a","volume":"14","author":"R Solanki","year":"2024","unstructured":"Solanki R, Makwana N, Kumar R, Joshi M, Patel A, Bhatia D, Sahoo DK (2024) Nanomedicines as a cutting-edge solution to combat antimicrobial resistance. RSC Adv 14:33568\u201333586. https:\/\/doi.org\/10.1039\/d4ra06117a","journal-title":"RSC Adv"},{"key":"2026_CR122","doi-asserted-by":"publisher","unstructured":"Song Z, Yu Y, Bai X, Jia Y, Tian J, Gu K, Zhao M, Zhou C, Zhang X, Wang H, Tang Y (2022) Pathogen-specific bactericidal method mediated by conjugative delivery of CRISPR-Cas13a targeting bacterial endogenous transcripts. Microbiol Spectr 10. https:\/\/doi.org\/10.1128\/spectrum.01300-22","DOI":"10.1128\/spectrum.01300-22"},{"key":"2026_CR160","doi-asserted-by":"publisher","unstructured":"Stone D, Long KR, LoprienoMA, De Silva Feelixge HS, Kenkel E, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Col\u00f3n-Thillet R, Klouser L, Weber N, Le C, WagonerJ, Goecker E, Li A, Eichholz K, Corey L, Tyrrell D, Greninger A, Huang MLW, Polyak SJ, Aubert M, Sagartz J, Jerome KR (2020) CRISPR-Cas9 geneediting of hepatitis B virus in chronically infected humanized mice. Molecular Therapy \u2013 Methods & Clinical Development 20:258\u2013275. https:\/\/doi.org\/10.1016\/j.omtm.2020.11.014","DOI":"10.1016\/j.omtm.2020.11.014"},{"key":"2026_CR123","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1124\/dmd.121.000403","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun D, Lu J, Zhang Y, Liu J, Liu Z, Yao B, Guo Y, Wang X (2021) Characterization of a Novel CYP1A2 Knockout Rat Model Constructed by CRISPR\/Cas9. Drug Metab Dispos 49:638\u2013647. https:\/\/doi.org\/10.1124\/dmd.121.000403","journal-title":"Drug Metab Dispos"},{"key":"2026_CR124","doi-asserted-by":"publisher","unstructured":"Tagliaferri T, Guimar\u00e3es N, De Paula Martins Pereira M, Vilela L, Horz H, Santos SD, Mendes T (2020) Exploring the potential of CRISPR-Cas9 under challenging conditions: facing high-copy plasmids and counteracting beta-lactam resistance in clinical strains of enterobacteriaceae. Frontiers in Microbiology 11. https:\/\/doi.org\/10.3389\/fmicb.2020.00578","DOI":"10.3389\/fmicb.2020.00578"},{"key":"2026_CR125","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14787210.2017.1400379","volume":"15","author":"M Trevisan","year":"2017","unstructured":"Trevisan M, Pal\u00f9 G, Barzon L (2017) Genome editing technologies to fight infectious diseases. Expert Rev Anti-infective Therapy 15:1001\u20131013. https:\/\/doi.org\/10.1080\/14787210.2017.1400379","journal-title":"Expert Rev Anti-infective Therapy"},{"key":"2026_CR155","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature03556","volume":"435","author":"F Urnov","year":"2005","unstructured":"Urnov F, Miller J, Lee Y-L, Beaus\u00e9jour C, Rock J, Augustus S, Jamieson A, Porteus M, Gregory P, Holmes M (2005) Highly efficient endogenous human gene correction using designed zinc-fingernucleases. Nature 435:646\u2013651. https:\/\/doi.org\/10.1038\/nature03556","journal-title":"Nature"},{"key":"2026_CR126","doi-asserted-by":"publisher","unstructured":"Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, Malakoti F, Alemi F, Qujeq D, Asemi Z, Yousefi B (2022) CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cell Mol Biol Lett 27. https:\/\/doi.org\/10.1186\/s11658-022-00348-2","DOI":"10.1186\/s11658-022-00348-2"},{"key":"2026_CR127","doi-asserted-by":"publisher","unstructured":"Vaidyanathan S, Salahudeen A, Sellers Z, Bravo D, Choi S, Batish A, Le W, Baik R, De La OS, Kaushik M, Galper N, Lee C, Teran C, Yoo J, Bao G, Chang E, Patel Z, Hwang P, Wine J, Milla C, Desai T, Nayak J, Kuo C, Porteus M (2019a) High-efficiency, selection-free gene repair in airway stem cells from cystic fibrosis patients rescues CFTR function in differentiated epithelia. Cell stem cell. https:\/\/doi.org\/10.1016\/j.stem.2019.11.002","DOI":"10.1016\/j.stem.2019.11.002"},{"key":"2026_CR128","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.stem.2019.11.002","volume":"26","author":"S Vaidyanathan","year":"2019","unstructured":"Vaidyanathan S, Salahudeen A, Sellers Z, Bravo D, Choi S, Batish A, Le W, Baik R, De La OS, Kaushik M, Galper N, Lee C, Teran C, Yoo J, Bao G, Chang E, Patel Z, Hwang P, Wine J, Milla C, Desai T, Nayak J, Kuo C, Porteus M (2019b) High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell 26:161\u2013171. https:\/\/doi.org\/10.1016\/j.stem.2019.11.002","journal-title":"Cell Stem Cell"},{"key":"2026_CR129","doi-asserted-by":"publisher","unstructured":"Vigouroux A, Bikard D (2020) CRISPR Tools to control gene expression in bacteria. Microbiol Mol Biol Rev 84. https:\/\/doi.org\/10.1128\/mmbr.00077","DOI":"10.1128\/mmbr.00077"},{"key":"2026_CR131","doi-asserted-by":"publisher","unstructured":"Walther J, Wilbie D, Tissingh V, \u00d6ktem M, Van Der Veen H, Lou B, Mastrobattista E (2022) Impact of formulation conditions on lipid nanoparticle characteristics and functional delivery of CRISPR RNP for gene knock-out and correction. Pharmaceutics 14. https:\/\/doi.org\/10.3390\/pharmaceutics14010213","DOI":"10.3390\/pharmaceutics14010213"},{"key":"2026_CR130","doi-asserted-by":"publisher","unstructured":"Walther J, Porenta D, Wilbie D, Seinen C, Benne N, Yang Q, De Jong OG, Lei Z, Mastrobattista E (2024) Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA\/sgRNA for gene editing in vitro and in vivo. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV:114207. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114207","DOI":"10.1016\/j.ejpb.2024.114207"},{"key":"2026_CR132","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/idr.s244885","volume":"13","author":"P Wan","year":"2020","unstructured":"Wan P, Cui S, Zhenbao, Chen L, Li X, Zhao R, Xiong W, Zeng Z (2020) Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System. Infect Drug Resist 13:1171\u20131178. https:\/\/doi.org\/10.2147\/idr.s244885","journal-title":"Infect Drug Resist"},{"key":"2026_CR134","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10565-017-9396-7","volume":"33","author":"W Wang","year":"2017","unstructured":"Wang W, Wang X (2017) Single-cell CRISPR screening in drug resistance. Cell Biol Toxicol 33:207\u2013210. https:\/\/doi.org\/10.1007\/s10565-017-9396-7","journal-title":"Cell Biol Toxicol"},{"key":"2026_CR136","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.apsb.2019.09.011","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Fang Z, Hong M, Yang D, Xie W (2019) Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sinica B 10:105\u2013112. https:\/\/doi.org\/10.1016\/j.apsb.2019.09.011","journal-title":"Acta Pharm Sinica B"},{"key":"2026_CR133","doi-asserted-by":"publisher","first-page":"e70780","DOI":"10.1096\/fj.202402401RR","volume":"39","author":"S Wang","year":"2025","unstructured":"Wang S, Zheng J, Zhang X, Zhao M, Li J, Su M, Qiu W (2025a) Genome-Wide CRISPR\u2010Cas9 Knockout Screening Identifies Genes Modulating Cisplatin\u2010Induced Cytotoxicity in Renal Proximal Tubule Epithelial Cells. FASEB J 39:e70780","journal-title":"FASEB J"},{"key":"2026_CR135","doi-asserted-by":"publisher","unstructured":"Wang X, Mi B, Lv J, Tang X, Huang J, Liu F, Xing Y, Wen X-Y, Wang Y, Zhong Y (2025b) Genome-wide CRISPR screening identifies CLDN1 as a central node in the anticancer mechanisms of berberine and as a therapeutic target in lung cancer. Oncol Lett 31. https:\/\/doi.org\/10.3892\/ol.2025.15415","DOI":"10.3892\/ol.2025.15415"},{"key":"2026_CR137","doi-asserted-by":"publisher","unstructured":"Wei T, Cheng Q, Min Y-L, Olson E, Siegwart D (2020) Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun 11. https:\/\/doi.org\/10.1038\/s41467-020-17029-3","DOI":"10.1038\/s41467-020-17029-3"},{"key":"2026_CR138","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10730-024-09538-1","volume":"37","author":"L Wiley","year":"2024","unstructured":"Wiley L, Cheek M, LaFar E, Xiaolu, Sekowski J, Tanguturi N, Iltis A (2024) The Ethics of Human Embryo Editing via CRISPR-Cas9 Technology: A Systematic Review of Ethical Arguments, Reasons, and Concerns. HEC Forum 37:267\u2013303. https:\/\/doi.org\/10.1007\/s10730-024-09538-1","journal-title":"HEC Forum"},{"key":"2026_CR139","doi-asserted-by":"publisher","unstructured":"Wu Y, Battalapalli D, Hakeem M, Selamneni V, Zhang P, Draz M, Ruan Z (2021) Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnol 19. https:\/\/doi.org\/10.1186\/s12951-021-01132-8","DOI":"10.1186\/s12951-021-01132-8"},{"key":"2026_CR140","doi-asserted-by":"publisher","unstructured":"Xu Yy Z, Sm W, Ly, Zhang R, Li K, Qian Zy, Xiao L (2025) Methods for detecting off-target effects of CRISPR\/Cas9. Biotechnology advances:108750. https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108750","DOI":"10.1016\/j.biotechadv.2025.108750"},{"key":"2026_CR141","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1124\/dmd.122.001111","volume":"51","author":"W Yang","year":"2023","unstructured":"Yang W, Zhao H, Dou Y, Wang P, Chang Q, Qiao X, Wang X, Xu C, Zhang Z, Zhang L (2023) CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR\/Cas9-Edited HepG2 Cells. Drug Metab Dispos 51:492\u2013498. https:\/\/doi.org\/10.1124\/dmd.122.001111","journal-title":"Drug Metab Dispos"},{"key":"2026_CR142","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41590-024-01943-5","volume":"25","author":"C Yeh","year":"2024","unstructured":"Yeh C, Aguirre K, Laveroni O, Kim S, Wang A, Liang B, Zhang X, Han L, Valbuena R, Bassik M, Kim Y-M, Plevritis S, Snyder M, Howitt B, Jerby L (2024) Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer. Nat Immunol 25:1943\u20131958. https:\/\/doi.org\/10.1038\/s41590-024-01943-5","journal-title":"Nat Immunol"},{"key":"2026_CR143","doi-asserted-by":"publisher","unstructured":"Yin X, Harmancey R, McPherson D, Kim H, Huang S (2023) Liposome-based carriers for CRISPR genome editing. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241612844","DOI":"10.3390\/ijms241612844"},{"key":"2026_CR147","doi-asserted-by":"publisher","unstructured":"Zhang X-H, Tee L, Wang X, Huang Q, Yang S (2015) Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol Therapy Nucleic Acids 4. https:\/\/doi.org\/10.1038\/mtna.2015.37","DOI":"10.1038\/mtna.2015.37"},{"key":"2026_CR146","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Ye B, Chen Z, Chen Z-S (2022) Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm Sinica B 13:982\u2013997. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.002","journal-title":"Acta Pharm Sinica B"},{"key":"2026_CR149","doi-asserted-by":"publisher","unstructured":"Zhang Z, Wang H, Yan Q, Cui J, Chen Y, Ruan S, Yang J, Wu Z, Han M, Huang S, Zhou Q, Zhang C, Hou B (2023) Genome-wide CRISPR\/Cas9 screening for drug resistance in tumors. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1284610","DOI":"10.3389\/fphar.2023.1284610"},{"key":"2026_CR145","doi-asserted-by":"publisher","unstructured":"Zhang H, Chen B, Wang Z, Peng K, Liu Y, Wang Z (2024) Resensitizing tigecycline- and colistin-resistant Escherichia coli using an engineered conjugative CRISPR\/Cas9 system. Microbiol Spectr 12. https:\/\/doi.org\/10.1128\/spectrum.03884-23","DOI":"10.1128\/spectrum.03884-23"},{"key":"2026_CR148","doi-asserted-by":"publisher","unstructured":"Zhang X, Dongyuan, Liu F, Genomics (2025) Proteom Bioinf 23. https:\/\/doi.org\/10.1093\/gpbjnl\/qzaf034","DOI":"10.1093\/gpbjnl\/qzaf034"},{"key":"2026_CR159","doi-asserted-by":"publisher","unstructured":"Zhang Z-Y, Ding Y, Ezhilarasan R, Lhakhang TW, Wang Q, Yang J, Modrek A, Zhang H, Tsirigos A, Futreal A, Draetta G, Verhaak R, Sulman E (2022) Lineage-coupledclonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma. Cell Discovery 8. https:\/\/doi.org\/10.1038\/s41421-022-00462-7","DOI":"10.1038\/s41421-022-00462-7"},{"key":"2026_CR150","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1021\/acscentsci.2c00609","volume":"8","author":"J Zhao","year":"2022","unstructured":"Zhao J, Tang Z, Selvaraju M, Johnson K, Douglas J, Gao P, Petrassi H, Wang MZ, Wang J (2022) Cellular Target Deconvolution of Small Molecules Using a Selection-Based Genetic Screening Platform. ACS Cent Sci 8:1424\u20131434. https:\/\/doi.org\/10.1021\/acscentsci.2c00609","journal-title":"ACS Cent Sci"},{"key":"2026_CR157","doi-asserted-by":"publisher","unstructured":"Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, Connelly J, Lim SA, Saravia J, Kc A, Pruett-Miller S, Chi H (2023) Single-cell CRISPR screens in vivo map T cellfate regulomes in cancer. Nature 624:154\u2013163. https:\/\/doi.org\/10.1038\/s41586-023-06733-x","DOI":"10.1038\/s41586-023-06733-x"},{"key":"2026_CR151","doi-asserted-by":"publisher","first-page":"e70121","DOI":"10.1111\/cbdd.70121","volume":"105","author":"A Zubair","year":"2025","unstructured":"Zubair A, Sujan A, Ali M, Hussain SM (2025) Current challenges with highly active antiretroviral therapy and new hope and horizon with CRISPR-CAS9 technology for HIV treatment. Chem Biol Drug Des 105:e70121","journal-title":"Chem Biol Drug Des"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-02026-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-026-02026-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-02026-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:43:44Z","timestamp":1788234224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-026-02026-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s10142-026-02026-4","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"24 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"240"}}